Summit Therapeutics Inc. Common Stock (SMMT) Financial Statements
Historical financial data — 22 statements covering FY2020–FY2022
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes...
Summit Therapeutics Inc. Common Stock's revenue decreased 61.0% year over year, from $1.8M to $705.0K.
Net income increased 11.1% over the same period, from $-88.6M to $-78.8M.
Operating cash flow grew 42.7% to $-41.6M.
Summit Therapeutics Inc. Common Stock maintains a negative net profit margin of -11174.8%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q1 FY2021 | $192.0K+3.8% | $-17.5M | N/A | $-16.9M | $-20.7M | $140.8M | N/A | $64.4M |
| Q2 FY2021 | $57.0K-70.3% | $-24.4M | N/A | $-23.7M | $-19.1M | $145.5M | N/A | $119.4M |
| Q3 FY2021 | $1.3M+2196.5% | $-19.6M | N/A | $-19.5M | $-23.6M | $128.7M | N/A | $102.3M |
| Q4 FY2021 | $251.0K-80.8% | $-27.1M | N/A | $-26.0M | $-9.2M | $113.4M | N/A | $83.3M |
| Q1 FY2022 | $250.0K-0.4% | $-21.4M | N/A | $-22.2M | $-19.0M | $116.5M | N/A | $64.4M |
| Q2 FY2022 | $235.0K-6.0% | $-16.8M | N/A | $-12.7M | $-19.2M | $95.7M | N/A | $51.3M |
| Q3 FY2022 | $220.0K-6.4% | $-21.4M | N/A | $-16.9M | $-8.6M | $155.3M | N/A | $133.2M |
| Q4 FY2022 | $0-100.0% | $-19.2M | N/A | $-20.3M | $5.2M | $664.2M | N/A | $126.7M |
Balance Sheet Summary (Latest Period)
Summit Therapeutics Inc. Common Stock (SMMT) Financial Statements & Revenue History
Summit Therapeutics Inc. Common Stock (SMMT) is a US-listed stock operating in the Healthcare sector, specifically the Pharmaceutical Preparations industry trading at $15.65 with a market capitalization of $12. This page provides 22 historical financial statements for Summit Therapeutics Inc. Common Stock, including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, Summit Therapeutics Inc. Common Stock reported revenue of $705000, a 61.0% decline from the prior year. The net profit margin of -11174.8% indicates the company is currently unprofitable..
SMMT Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows Summit Therapeutics Inc. Common Stock's revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether SMMT is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track SMMT's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently Summit Therapeutics Inc. Common Stock converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of SMMT's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use SMMT Financial Data
Investors use Summit Therapeutics Inc. Common Stock's financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare SMMT's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how SMMT's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View SMMT's financial health score, earnings, and pre-market pricing.
Financial data is sourced from Summit Therapeutics Inc. Common Stock's SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.SMMT trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.